Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model

Journal of Extracellular Vesicles

Volumn 6, Issue 1, 2017, Pages

  Yang, Vicky K ^a   Loughran, Kerry A ^a   Meola, Dawn M ^a   Juhr, Christine M ^a   Thane, Kristen E ^a   Davis, Airiel M ^a   Hoffman, Andrew M ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

animal models of human disease; biomarker; exosome; heart failure; miRNA; mitral valve

Indexed keywords

CIRCULATING EXOSOME MICRORNA; CIRCULATING MICRORNA; MICRORNA; MICRORNA 181C; MICRORNA 495; MICRORNA 599; MICRORNA 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANINE MODEL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; EXOSOME; FALSE POSITIVE RESULT; FEMALE; GENE CLUSTER; GENE EXPRESSION LEVEL; GENE INTERACTION; GENE OVEREXPRESSION; GENE REPRESSION; HEART FAILURE; JUVENILE ANIMAL; MALE; MITRAL VALVE DISEASE; MITRAL VALVE PROLAPSE; MOLECULAR PATHOLOGY; MYXOMATOUS MITRAL VALVE DISEASE; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 85040367145     PISSN: None     EISSN: 20013078     Source Type: Journal    
DOI: 10.1080/20013078.2017.1350088     Document Type: Article

References (41)

1. Hagler MA, Hadley TM, Zhang H, et al. TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves. Cardiovasc Res. 2013;99:1–12.
2. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. JACC. 2008;52:e1–142.
3. Borgarelli M, Buchanan JW., Historical review, epidemiology and natural history of degenerative mitral valve disease. J Vet Cardiol. 2012;14:93–101.
4. Ha M, Kim VN., Regulation of microRNA biogenesis. Nat Rev. 2014;15:509–524.
5. Chen Y, Wakili R, Xiao J, et al. Detailed characterization of microRNA changes in a canine heart failure model: relationship to arrhythmogenic structural remodeling. J Mol Cell Cardiol. 2014;77:113–124.
6. Zhang Y, Zheng S, Geng Y, et al. MicroRNA profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1. PLoS One. 2015;10:e0122674.
7. Li Q, Freeman LM, Rush, JE, et al. Expression profiling of circulating microRNAs in canine myxomatous mitral valve disease. In J Mol Sci. 2015;16:14098–14108.
8. Hulanicka M, Garncarz M, Parzeniecka-Jaworska M, et al. Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds. BMC Vet Res. 2014;10:205–212.
9. Andaloussi SE, Mager I, Breakefield XO, et al. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev. 2013;12:347–357.
10. Barile L, Moccetti T, Marban E, et al. Roles of exosomes in cardioprotection. Eur Heart J. 2016;ehw304.
11. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23:1142–1150.
12. Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2:20360.
13. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289.
14. Murray MJ, Raby K, Saini HK, et al. Solid tumors of childhood display specific serum microRNA profiles. Cancer Epidemiol Biomarkers Prev. 2014;24:350–361.
15. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev. 2012;13:358–369.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Soc B. 1995;57:289–300.
17. Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005.
18. Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146–D152.
19. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374–378.
20. van der Pol E, Coumans FAW, Grootemaat AE, et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost. 2014;12:1182–1192.
21. Wang L, Ma LK, Fan H, et al. MicroRNA-9 regulates cardiac fibrosis by targeting PDGFR-β in rats. J Physiol Biochem. 2016;72:213–223.
22. Das S, Ferlito M, Kent OA, et al. Nuclear microRNA regulates the mitochondrial genome in the heart. Circ Res. 2012;110:1596–1603.
23. Das S, Bedja D, Campbell N, et al. miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS One. 2014;9:e96820.
24. Ouyang YB, Lu Y, Yue S, et al. miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion. 2012;12:213–219.
25. Wang H, Li J, Chi H, et al. MicroRNA-181c targets Bcl-2 and regulates mitochondrial morphology in myocardial cells. J Cell Mol Med. 2015;19:2084–2097.
26. Clark AL, Maruyama S, Sano S, et al. miR-410 and miR-495 are dynamically regulated in diverse cardiomyopathies and their inhibition attenuates pathological hypertrophy. PLoS One. 2016;11:e0151515.
27. Clark AL, Naya FJ. MicroRNAs in the myocyte enhancer factor 2 (MEF2)-regulated Gtl2-Dio3 noncoding RNA locus promote cardiomyocyte proliferation by targeting the transcriptional coactivator Cited2. J Biol Chem. 2015;290:23162–23172.
28. Xie B, Zhang C, Jiang S. miR-599 inhibits vascular smooth muscle cells proliferation and migration by targeting TGFB2. PLoS One. 2015;10:e0141512.
29. Fan Y, Siklenka K, Arora SK, et al. miRNet - dissecting miRNA-target interactions and functional associations through network-based visual analysis. Nucl Acids Res. 2016;44:W135–W141.
30. Fritz CC, Zapp ML, Green MR. A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature. 1995;376:530–533.
31. Kertai MD, Qi W, Li YJ, et al. Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving β-blockers. J Mol Cell Cardiol. 2016;92:109–115.
32. Hayano S, Takefuji M, Maeda K, et al. Akt-dependent Girdin phosphorylation regulates repair processes after acute myocardial infarction. J Mol Cell Cardiol. 2015;88:55–63.
33. Xu T, Wu BM, Yao HW, et al. Novel insights into TRPM7 function in fibrotic diseases: a potential therapeutic target. J Cell Physiol. 2015;230:1163–1169.
34. Khananshvili D. The SLC8 gene family of sodium–calcium exchangers (NCX)–Structure, function, and regulation in health and disease. Mol Aspects Med. 2013;34:220–235.
35. Hille S, Dierck F, Kuhl C, et al. Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling. Cardiovasc Res. 2016;110:381–394.
36. Drosatos K, Pollak NM, Pol CJ, et al. Cardiac myocyte KLF5 regulates Ppara expression and cardiac function. Circ Res. 2016;118:241–253.
37. Liu X, Xiao J, Zhu H, et al. miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab. 2015;21:584–595.
38. Antonicka H, Sasarman F, Nishimura T. The mitochondrial RNA-binding protein GRSF1 localizes to RNA granules and is required for posttranscriptional mitochondrial gene expression. Cell Metab. 2013;17:386–398.
39. Aupperle H, Marz I, Thielebein J. Immunohistochemical characterization of the extracellular matrix in normal mitral valves and in chronic valve disease (endocardiosis) in dogs. Res Vet Sci. 2009;87:277–283.
40. Aupperle H, Marz I, Thielebein J, et al. Expression of transforming growth factor-β1, -β2 and -β3 in normal and diseased canine mitral valves. J Comp Path. 2008;139:97–107.
41. Geirsson A, Singh M, Ali R, et al. Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Circulation. 2012;126(suppl 1):S189–S197.